J&J MedTech‘s Abiomed today reported positive findings for routine use of its Impella CP heart pump system.
Dr. Jacob Møller, the study’s principal investigator, presented findings at the European Society of Cardiology (ESC) Congress in Madrid. Investigators simultaneously published outcomes in the New England Journal of Medicine (NEJM).
Impella CP, the world’s smallest heart pump, is inserted into the heart to temporarily take over the heart’s pumping function. It allows the heart to rest and recover while maintaining the flow of oxygenated blood throughout the body.
The DanGer Shock trial evaluated Impella CP in patients who had a heart attack with cardiogenic shock. At up to 10 years, compared to the standard of care, Impella CP led to an absolute mortality reduction of 16.3%. When compared to the control, Impella CP patients gained an average of 600 additional days alive, too.
Abiomed said the absolute mortality reduction of 16.3% at up to 10 years marks an increase from the initial six-month data. That found that routine use of Impella CP reduced the risk of mortality by 12.7%.
According to the company, Impella CP is the first mechanical circulatory support system (MCS) proven in a randomized controlled trial to provide short-term and long-term survival benefits in patients with cardiogenic shock due to ST-elevation myocardial infarction (STEMI), also known as an acute heart attack.
“The long-term data from the DanGer Shock RCT released today validates the original findings and confirms that the survival benefit of Impella CP is durable and increases year-over-year,” said Dr. Navin Kapur, chief medical and scientific officer for heart recovery, J&J MedTech.
